Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BA3021 |
Synonyms | |
Therapy Description |
BA3021 (CAB-ROR2-ADC) is a conditionally active anti-ROR2 antibody in conjugation with a cytotoxic agent that preferentially binds and delivers cytotoxicity to Ror2-expressing cells in tumors, which potentially induces antitumor activity (Cancer Res (2018) 78 (13_Supplement): 833). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BA3021 | CAB-ROR2-ADC|BA 3021|Ozuriftamab Vedotin | BA3021 (CAB-ROR2-ADC) is a conditionally active anti-ROR2 antibody in conjugation with a cytotoxic agent that preferentially binds and delivers cytotoxicity to Ror2-expressing cells in tumors, which potentially induces antitumor activity (Cancer Res (2018) 78 (13_Supplement): 833). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03504488 | Phase Ib/II | BA3021 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors | Active, not recruiting | USA | POL | GRC | ESP | 2 |
NCT05271604 | Phase II | BA3021 | A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Recruiting | USA | 0 |